Ország: Ausztrália
Nyelv: angol
Forrás: Department of Health (Therapeutic Goods Administration)
calcium hydrogen phosphate,colecalciferol
Pharmacare Laboratories Pty Ltd
calcium hydrogen phosphate,colecalciferol
Medicine Listed
Listed
WARNINGS LIMITATIONS OF USE Rikodeine should only be used when your doctor or pharmacist decides that other treatment options are not able to effectively manage your cough, or you cannot tolerate them. HAZARDOUS AND HARMFUL USE Rikodeine poses risks of abuse, misuse and addiction which can lead to overdose and death. LIFE THREATENING RESPIRATORY DEPRESSION Rikodeine can cause life-threatening or fatal breathing problems (slow, shallow, unusual or no breathing) even when used as recommended. These problems can occur at any time during use, but the risk is higher when first starting Rikodeine and after a dose increase, if you are older, or have an existing problem with your lungs. USE OF OTHER MEDICINES WHILE USING RIKODEINE USING RIKODEINE WITH OTHER MEDICINES THAT CAN MAKE YOU FEEL DROWSY SUCH AS SLEEPING TABLETS (E.G., BENZODIAZEPINES), OTHER PAIN RELIEVERS, ANTIHISTAMINES, ANTIDEPRESSANTS, ANTIPSYCHOTICS, GABAPENTINOIDS (E.G., GABAPENTIN AND PREGABALIN), CANNABIS AND ALCOHOL MAY RESULT IN SEVERE DROWSINESS, DECREASED AWARENESS, BREATHING PROBLEMS, COMA AND DEATH. You must not drink alcohol while using Rikodeine. RIKODEINE ® ORAL LIQUID (rye-co-deen) R I K O D E I N E O R A L L I Q U I D ACTIVE INGREDIENT(S): _Dihydrocodeine tartrate and sorbitol (die-hydro-co-deen tahr-treyt + sore-be-tol)_ CONSUMER MEDICINE INFORMATION (CMI) This leaflet provides important information about using Rikodeine. YOU SHOULD ALSO SPEAK TO YOUR DOCTOR OR PHARMACIST IF YOU WOULD LIKE FURTHER INFORMATION OR IF YOU HAVE ANY CONCERNS OR QUESTIONS ABOUT USING RIKODEINE. WHERE TO FIND INFORMATION IN THIS LEAFLET: 1. Why am I taking Rikodeine? 2. What should I know before I take Rikodeine? 3. What if I am taking other medicines? 4. How do I take Rikodeine? 5. What should I know while taking Rikodeine? 6. Are there any side effects? 7. Product details 1. WHY AM I TAKING RIKODEINE? Rikodeine is a cough suppressant and contains the active ingredients, dihydrocodeine tartrate and sorbitol. Rikodeine is used to give temporary relief for an unpro Olvassa el a teljes dokumentumot
1 AUSTRALIAN PRODUCT INFORMATION – RIKODEINE ® (DIHYDROCODEINE TARTRATE AND SORBITOL) ORAL LIQUID 1 NAME OF THE MEDICINE Dihydrocodeine tartrate and Sorbitol. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 10 mL of Rikodeine Oral Liquid contains dihydrocodeine tartrate 19 mg, and sorbitol 4.4 g. It also contains sucrose, citric acid, methyl hydroxybenzoate, amaranth, strawberry flavour 73858 and water. Excipients with known effects: sugars, hydroxybenzoates, sorbitol (26.4 g per 60 mL (maximum recommended daily dose). 3 PHARMACEUTICAL FORM Oral liquid – pink coloured solution 4 CLINICAL PARTICULARS 4.1 T HERAPEUTIC INDICATIONS For relief of stubborn, unproductive cough. 4.2 D OSE AND METHOD OF ADMINISTRATION AGE DOSAGE HOW OFTEN Adults and Children 12 years and over 5 to 10 mL Every 4-6 hours as required Children between 6-11 years Use in children ages 6-11 years only on the advice of a doctor, pharmacist or nurse practitioner 2.5 to 5 mL Do not use in children aged less than 6 years Initial dosage should be reduced in the elderly as there may be a marked variability in pharmacokinetics in the elderly (See _Metabolism and Excretion in section 5.2 Pharmacokinetic Properties_). WARNINGS HAZARDOUS AND HARMFUL USE Rikodeine Oral Liquid contains dihydrocodeine and poses risks of hazardous and harmful use which can lead to overdose and death. Assess the patient’s risk of hazardous and harmful use before prescribing and monitor the patient regularly during treatment (see _section 4.4. Special Warnings and Precautions for Use_). LIFE THREATENING RESPIRATORY DEPRESSION Serious, life-threatening or fatal respiratory depression may occur with the use of Rikodeine Oral Liquid. Be aware of situations which increase the risk of respiratory depression, modify dosing in patients at risk and monitor patients closely, especially on initiation or following a dose increase (see _section 4.4 Special _ _Warnings and Precautions for Use_). CONCOMITANT USE OF BENZODIAZEPINES AND OTHER CENTRAL NERVOUS SYSTEM (CNS) DEPRESSANTS, IN Olvassa el a teljes dokumentumot